Ligand Pharmaceuticals Incorporated, a biotechnology company, engages in the acquisition and development of royalty revenue generating assets in the United States. The company's assets include PROMACTA, an oral thrombopoietin receptor agonist therapy for the treatment of adult patients with chronic immune thrombocytopenic purpura; Kyprolis for the treatment of multiple myeloma; AVINZA, a pain therapeutic; Viviant/Conbriza for the treatment of postmenopausal osteoporosis; Nexterone, an injectable formulation; and Viviant (bazedoxifene) for the treatment of postmenopausal osteoporosis. Its late-stage development programs comprise PROMACTA, which is in is in Phase II clinical studies for the treatment of oncology-related thrombocytopenia in patients with solid tumors, sarcoma, and Myelodysplastic Syndrome. The company's late-stage development programs also include Merck Captisol program that is in Phase III studies; Captisol-enabled Clopidogrel, which is in Phase III studies; RE-021 program, a dual acting receptor antagonist that is in various stages of development for indications of severe kidney diseases; Dinaciclib that is in Phase IIb/III adaptive clinical trials for the treatment of patients with refractory chronic lymphocytic leukemia; and Beta-Secretase Inhibitor, which is in Phase II/III studies for treating Alzheimer's disease. In addition, its late-stage development programs comprise Captisol-enabled Delafloxacin, a Phase III clinical trial product for the management of acute seizure disorder; and Captisol-enabled Delafloxacin that is in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections. The company has alliances with GlaxoSmithKline, Onyx Pharmaceuticals, Merck, Pfizer, Baxter International, Bristol-Myers Squibb, Celgene, Lundbeck Inc., Eli Lilly and Co., Spectrum Pharmaceuticals, and The Medicines Company. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in La Jolla, California.